Difference between revisions of "Medroxyprogesterone acetate (MPA)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
 
(4 intermediate revisions by the same user not shown)
Line 5: Line 5:
 
*[[Breast cancer - historical|Breast cancer]]
 
*[[Breast cancer - historical|Breast cancer]]
 
*[[Renal cell carcinoma - historical|Renal cell carcinoma]]
 
*[[Renal cell carcinoma - historical|Renal cell carcinoma]]
 +
 +
==History of changes in FDA indication==
 +
*1959-06-18: Initial approval
 +
==History of changes in EMA indication==
 +
*1959-08-20: EURD
  
 
==Also known as==
 
==Also known as==
Line 15: Line 20:
 
[[Category:Subcutaneous medications]]
 
[[Category:Subcutaneous medications]]
  
[[Category:Endocrine therapeutic]]
+
[[Category:Progestins]]
  
 
[[Category:Endometrial cancer medications]]
 
[[Category:Endometrial cancer medications]]
Line 23: Line 28:
  
 
[[Category:FDA approved in 1959]]
 
[[Category:FDA approved in 1959]]
 
+
[[Category:EMA approved in 1959]]
 
[[Category:Stub]]
 
[[Category:Stub]]

Latest revision as of 10:42, 4 July 2023

Diseases for which it is used

Diseases for which it was used

History of changes in FDA indication

  • 1959-06-18: Initial approval

History of changes in EMA indication

  • 1959-08-20: EURD

Also known as

  • Generic names: medroxyprogesterone acetate, MPA
  • Brand names: Depo-Provera, Provera